## Steven E Feldon

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7470006/publications.pdf

Version: 2024-02-01

118 5,133 39 67 papers citations h-index g-index

121 121 121 3566

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease. Survey of Ophthalmology, 2022, 67, 858-874.	1.7	3
2	Re: Fairless etÂal.: Ophthalmology departments remain among the least diverse clinical departments at United States medical schools (Ophthalmology. 2021;128:1129-1134). Ophthalmology, 2022, 129, e7-e8.	2.5	0
3	More than Meets the Eye: The Aryl Hydrocarbon Receptor is an Environmental Sensor, Physiological Regulator and a Therapeutic Target in Ocular Disease. Frontiers in Toxicology, 2022, 4, 791082.	1.6	8
4	MicroRNA-130a Is Elevated in Thyroid Eye Disease and Increases Lipid Accumulation in Fibroblasts Through the Suppression of AMPK., 2021, 62, 29.		14
5	Variability of Retinal Vessel Tortuosity Measurements Using a Semiautomated Method Applied to Fundus Images in Subjects With Papilledema. Translational Vision Science and Technology, 2021, 10, 32.	1.1	6
6	Retinal vessel diameter changes after 6 months of treatment in the Idiopathic Intracranial Hypertension Treatment Trial. British Journal of Ophthalmology, 2020, 104, 1430-1434.	2.1	4
7	The aryl hydrocarbon receptor pathway controls matrix metalloproteinase-1 and collagen levels in human orbital fibroblasts. Scientific Reports, 2020, 10, 8477.	1.6	18
8	Salinomycin inhibits proliferative vitreoretinopathy formation in a mouse model. PLoS ONE, 2020, 15, e0243626.	1.1	5
9	TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts. , 2019, 60, 4336.		39
10	The polyether ionophore salinomycin targets multiple cellular pathways to block proliferative vitreoretinopathy pathology. PLoS ONE, 2019, 14, e0222596.	1.1	11
11	Proton pump inhibitors attenuate myofibroblast formation associated with thyroid eye disease through the aryl hydrocarbon receptor. PLoS ONE, 2019, 14, e0222779.	1.1	14
12	Probability of Success in the Ophthalmology Residency Match: Three-Year Outcomes Analysis of San Francisco Matching Program Data. Journal of Academic Ophthalmology (2017), 2018, 10, e150-e157.	0.2	25
13	The Relationship Between Optic Disc Volume, Area, and Frisén Score in Patients With Idiopathic Intracranial Hypertension. American Journal of Ophthalmology, 2018, 195, 101-109.	1.7	15
14	The Effect of Treatment of Idiopathic Intracranial Hypertension on Prevalence of Retinal and Choroidal Folds. American Journal of Ophthalmology, 2017, 176, 77-86.	1.7	22
15	Current Shortcomings of Camera Screening. JAMA Internal Medicine, 2017, 177, 1539.	2.6	O
16	Author Response: Choroidal Folds in Astronauts. , 2016, 57, 593.		0
17	Integrating the Internship into Ophthalmology Residency Programs. Ophthalmology, 2016, 123, 2037-2041.	2.5	8
18	The Aryl Hydrocarbon Receptor and Its Ligands Inhibit Myofibroblast Formation and Activation. American Journal of Pathology, 2016, 186, 3189-3202.	1.9	31

#	Article	IF	Citations
19	Retinal and Choroidal Folds in Papilledema. , 2015, 56, 5670.		74
20	Photographic Reading Center of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT): Methods and Baseline Results., 2015, 56, 3292.		24
21	Salinomycin and Other Polyether Ionophores Are a New Class of Antiscarring Agent. Journal of Biological Chemistry, 2015, 290, 3563-3575.	1.6	32
22	Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial. Ophthalmology, 2015, 122, 1939-1945.e2.	2.5	66
23	Thy1 (CD90) controls adipogenesis by regulating activity of the Src family kinase, Fyn. FASEB Journal, 2015, 29, 920-931.	0.2	55
24	Mapracorat, a selective glucocorticoid receptor agonist, upregulates RelB, an anti-inflammatory nuclear factor-kappaB protein, in human ocular cells. Experimental Eye Research, 2014, 127, 290-298.	1.2	18
25	The Immunopathology of Giant Cell Arteritis. Journal of Neuro-Ophthalmology, 2014, 34, 100-101.	0.4	1
26	The Idiopathic Intracranial Hypertension Treatment Trial. JAMA Neurology, 2014, 71, 693.	4.5	336
27	The Idiopathic Intracranial Hypertension Treatment Trial. Journal of Neuro-Ophthalmology, 2014, 34, 107-117.	0.4	69
28	Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss. JAMA - Journal of the American Medical Association, 2014, 311, 1641.	3.8	383
29	Baseline OCT Measurements in the Idiopathic Intracranial Hypertension Treatment Trial, Part II: Correlations and Relationship to Clinical Features. Investigative Ophthalmology and Visual Science, 2014, 55, 8173-8179.	3.3	89
30	Baseline OCT Measurements in the Idiopathic Intracranial Hypertension Treatment Trial, Part I: Quality Control, Comparisons, and Variability. Investigative Ophthalmology and Visual Science, 2014, 55, 8180-8188.	3.3	74
31	Visual Fields in Retinal Disease. , 2013, , 307-328.		0
32	Orbital Fibroblasts From Thyroid Eye Disease Patients Differ in Proliferative and Adipogenic Responses Depending on Disease Subtype., 2013, 54, 7370.		48
33	Lemierre Syndrome Causing Bilateral Cavernous Sinus Thrombosis. Journal of Neuro-Ophthalmology, 2012, 32, 341-344.	0.4	18
34	Reliability of Estimating Ductions in Thyroid Eye Disease. Ophthalmology, 2012, 119, 382-389.	2.5	45
35	Electrophilic PPARÎ <sup>3</sup> ligands inhibit corneal fibroblast to myofibroblast differentiation inÂvitro: A potentially novel therapy for corneal scarring. Experimental Eye Research, 2012, 94, 136-145.	1.2	22
36	The Aryl Hydrocarbon Receptor Ligand ITE Inhibits $TGF\hat{I}^21$ -Induced Human Myofibroblast Differentiation. American Journal of Pathology, 2011, 178, 1556-1567.	1.9	51

3

#	Article	IF	CITATIONS
37	Reply re: "Sinus Opacification Associated With Exacerbation of Thyroid Eye Disease― Ophthalmic Plastic and Reconstructive Surgery, 2011, 27, 304-305.	0.4	O
38	Coup de Sabre Presenting With Worsening Diplopia and Enophthalmos. Ophthalmic Plastic and Reconstructive Surgery, 2011, 27, e97-e98.	0.4	5
39	Ocular Fibroblast Diversity: Implications for Inflammation and Ocular Wound Healing. , 2011, 52, 4859.		44
40	Peroxisome Proliferator-activated Receptor $\hat{I}^3$ Ligands Inhibit Transforming Growth Factor- $\hat{I}^2$ -induced, Hyaluronan-dependent, T Cell Adhesion to Orbital Fibroblasts. Journal of Biological Chemistry, 2011, 286, 18856-18867.	1.6	29
41	Sinus Opacification Associated With Exacerbation of Thyroid Eye Disease. Ophthalmic Plastic and Reconstructive Surgery, 2010, 26, 233-237.	0.4	O
42	Novel anti-adipogenic activity produced by human fibroblasts. American Journal of Physiology - Cell Physiology, 2010, 299, C672-C681.	2.1	33
43	Mast Cell-derived Prostaglandin D2 Controls Hyaluronan Synthesis in Human Orbital Fibroblasts via DP1 Activation. Journal of Biological Chemistry, 2010, 285, 15794-15804.	1.6	34
44	Utilization, Diagnosis, Treatment and Cost of Migraine Treatment in the Emergency Department. Headache, 2009, 49, 1163-1173.	1.8	21
45	Late Onset Optic Neuropathy in Methylmalonic and Propionic Acidemia. American Journal of Ophthalmology, 2009, 147, 929-933.	1.7	53
46	Rationale for Radiotherapy in Thyroid Eye Disease. American Journal of Ophthalmology, 2009, 148, 818-819.	1.7	8
47	Retinal Arteriolar Spasm During Transient Monocular Visual Loss in Eosinophilic Vasculitis. Journal of Neuro-Ophthalmology, 2009, 29, 58-61.	0.4	5
48	The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC). Journal of Neuro-Ophthalmology, 2009, 29, 259-261.	0.4	3
49	Visual Fields at Follow-up in the Ischemic Optic Neuropathy Decompression Trial. Ophthalmology, 2008, 115, 1809-1817.	2.5	36
50	Improvement of Thyroid Eye Disease Following Treatment with the Cyclooxygenase-2 Selective Inhibitor Celecoxib. Thyroid, 2008, 18, 911-914.	2.4	14
51	Optic neuritis and the risk of multiple sclerosis—what can we learn from a brain MRI scan?. Nature Clinical Practice Neurology, 2008, 4, 532-533.	2.7	2
52	Immune Mechanisms in Thyroid Eye Disease. Thyroid, 2008, 18, 959-965.	2.4	140
53	The eye and thyroid disease. Current Opinion in Ophthalmology, 2008, 19, 499-506.	1.3	64
54	Efficacy of Corticosteroids and External Beam Radiation in the Management of Moderate to Severe Thyroid Eye Disease. Journal of Neuro-Ophthalmology, 2007, 27, 205-214.	0.4	42

#	Article	IF	CITATIONS
55	Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension. Neurosurgical Focus, 2007, 23, E6.	1.0	85
56	Relaxed Muscle Positioning Technique. Ophthalmology, 2007, 114, 2104-2105.	2.5	3
57	Activated Human T Lymphocytes Express Cyclooxygenase-2 and Produce Proadipogenic Prostaglandins that Drive Human Orbital Fibroblast Differentiation to Adipocytes. American Journal of Pathology, 2006, 169, 1183-1193.	1.9	93
58	North American Neuro-Ophthalmology Fellowships to Begin Voluntary Participation in Standard Guidelines Program in July 2006. Journal of Neuro-Ophthalmology, 2006, 26, 81.	0.4	0
59	Development and validation of a computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression Trial. BMC Ophthalmology, 2006, 6, 34.	0.6	11
60	More Than Structural Cells, Fibroblasts Create and Orchestrate the Tumor Microenvironment. Immunological Investigations, 2006, 35, 297-325.	1.0	99
61	Visual Fields in Retinal Disease. , 2006, , 235-252.		0
62	Isolation and Phenotypic Characterization of Lung Fibroblasts., 2005, 117, 115-127.		63
63	The relation of Graves' ophthalmopathy to circulating thyroid hormone status. British Journal of Ophthalmology, 2004, 88, 72-74.	2.1	27
64	A novel ELISpot method for adherent cells. Journal of Immunological Methods, 2004, 291, 63-70.	0.6	16
65	Computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression Trial: methods, baseline fields, and six-month longitudinal follow-up. Transactions of the American Ophthalmological Society, 2004, 102, 269-303.	1.4	7
66	Surgical quality assurance in the Ischemic Optic Neuropathy Decompression Trial (IONDT). Contemporary Clinical Trials, 2003, 24, 294-305.	2.0	10
67	Comparison of information obtained by operative note abstraction with that recorded on a standardized data collection form. Surgery, 2003, 133, 324-330.	1.0	27
68	The Eger Macular Stressometer: pilot study. American Journal of Ophthalmology, 2003, 136, 314-317.	1.7	8
69	Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes. American Journal of Pathology, 2003, 163, 1291-1300.	1.9	237
70	Sweep Visual Evoked Potential Evaluation of Contrast Sensitivity in Alzheimer's Dementia. , 2003, 44, 875.		54
71	The fellow eye in naion: report from the ischemic optic neuropathy decompression trial follow-up study. American Journal of Ophthalmology, 2002, 134, 317-328.	1.7	284
72	Correction of restricted extraocular muscle motility in surgical management of strabismus in graves' ophthalmopathy1 1The authors have no proprietary interest in any of the materials used in this study Ophthalmology, 2002, 109, 384-388.	2.5	76

#	Article	IF	Citations
73	THE EPIDEMIOLOGY OF GIANT CELL ARTERITIS. Evidence-Based Eye Care, 2002, 3, 16-17.	0.2	o
74	Exudative retinal detachment in relapsing polychondritis. Ophthalmology, 2001, 108, 1156-1159.	2.5	12
75	The epidemiology of giant cell arteritis. Ophthalmology, 2001, 108, 1145-1149.	2.5	96
76	Radiation therapy for Graves' ophthalmopathy: trick or treat?. Ophthalmology, 2001, 108, 1521-1522.	2.5	26
77	Orbital presentations of giant cell arteritis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2001, 239, 509-513.	1.0	46
78	The role of restricted motility in determining outcomes for vertical strabismus surgery in graves' ophthalmopathy. Ophthalmology, 2000, 107, 545-549.	2.5	52
79	Assessment of disease severity. , 2000, , 39-57.		5
80	Age-related deterioration of motion perception and detection. Graefe's Archive for Clinical and Experimental Ophthalmology, 1998, 236, 269-273.	1.0	65
81	Extraocular muscle changes in experimental orbital venous stasis: some similarities to graves' orbitopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 1996, 234, 331-336.	1.0	21
82	Septic cavernous sinus thrombosis following transsphenoidal craniotomy. Journal of Neurosurgery, 1996, 85, 949-952.	0.9	10
83	Choroidal Effusion as a Mechanism for Transient Myopia Induced by Hydrochlorothiazide and Triamterene. American Journal of Ophthalmology, 1995, 120, 395-397.	1.7	44
84	Refractive changes induced by electrocautery of the rabbit anterior lens capsule. Journal of Cataract and Refractive Surgery, 1994, 20, 132-137.	0.7	2
85	Late Onset Dysthyroid Optic Neuropathy. Thyroid, 1994, 4, 213-216.	2.4	15
86	Classification of Graves' Ophthalmopathy. Thyroid, 1993, 3, 171-171.	2.4	4
87	Management of Graves' Ophthalmopathy With Optic Nerve Involvement. Mayo Clinic Proceedings, 1993, 68, 616-617.	1.4	2
88	Orbital lymphoma in a patient with Felty's syndrome British Journal of Ophthalmology, 1992, 76, 173-174.	2.1	2
89	Corneal Topographic Changes Following Strabismus Surgery in Graves?? Disease. Cornea, 1992, 11, 36-40.	0.9	48
90	Late Overcorrection of Hypotropia in Graves Ophthalmopathy. Ophthalmology, 1992, 99, 356-360.	2.5	74

#	Article	IF	Citations
91	Graves Exophthalmos Unrelated to Extraocular Muscle Enlargement. Ophthalmology, 1991, 98, 1495-1499.	2.5	74
92	Macular degeneration secondary to benign orbital mass°. Orbit, 1991, 10, 1-3.	0.5	0
93	Graves' ophthalmopathy: V. Aetiology of upper eyelid retraction in Graves' ophthalmopathy British Journal of Ophthalmology, 1990, 74, 484-485.	2.1	42
94	Graves' Ophthalmopathy. Archives of Internal Medicine, 1990, 150, 948.	4.3	7
95	Graves' Ophthalmopathy. JAMA Ophthalmology, 1990, 108, 1568.	2.6	18
96	Visual Loss Caused by Rapidly Progressive Intracranial Meningiomas During Pregnancy. Ophthalmology, 1990, 97, 18-21.	2.5	48
97	Anterior ischemic optic neuropathy: Classification of field defects by Octopusâ,, automated static perimetry. Graefe's Archive for Clinical and Experimental Ophthalmology, 1988, 226, 206-212.	1.0	30
98	Graves' ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography British Journal of Ophthalmology, 1988, 72, 678-682.	2.1	79
99	Graves' ophthalmopathy: I. Simple CT estimates of extraocular muscle volume British Journal of Ophthalmology, 1988, 72, 674-677.	2.1	70
100	Graves' ophthalmopathy: III. Effect of transantral orbital decompression on optic neuropathy British Journal of Ophthalmology, 1988, 72, 683-687.	2.1	40
101	Opthalmic Manifestations of Maxillary Sinus Mucoceles. Ophthalmology, 1987, 94, 1013-1019.	2.5	43
102	Quantitative Computed Tomography of Graves' Ophthalmopathy. JAMA Ophthalmology, 1985, 103, 213.	2.6	102
103	Clinical Classification of Graves' Ophthalmopathy. JAMA Ophthalmology, 1984, 102, 1469.	2.6	112
104	Reverse Collier's Sign: Pseudoblepharoptosis Associated With Downgaze Paralysis. American Journal of Ophthalmology, 1983, 95, 120-121.	1.7	3
105	Cause of Enophthalmos Secondary to Maxillary Sinus Mucocele. American Journal of Ophthalmology, 1983, 95, 838-840.	1.7	16
106	Bromocriptine Treatment of Prolactin-secreting Tumors: Surgical Implications. Neurosurgery, 1983, 12, 640-642.	0.6	60
107	Oculomotor Effects of Intermittent Conduction Block in Myasthenia Gravis and Guillain-Barré Syndrome. Archives of Neurology, 1982, 39, 497.	4.9	27
108	Clinical Significance of Extraocular Muscle Volumes in Graves' Ophthalmopathy. JAMA Ophthalmology, 1982, 100, 1266.	2.6	104

#	Article	IF	CITATIONS
109	Clinical and Computed Tomographic Findings in the Foster Kennedy Syndrome. American Journal of Ophthalmology, 1982, 93, 317-322.	1.7	16
110	Eye movement recordings in gyrate atrophy of the retina. Experimental Eye Research, 1982, 34, 293-295.	1.2	0
111	Reversible choroidal vascular insufficiency without infarction in temporal arteritis. Graefe's Archive for Clinical and Experimental Ophthalmology, 1982, 218, 327-330.	1.0	6
112	DISORDERED INHIBITION IN INTERNUCLEAR OPTHALMOPLEGIA. Brain, 1980, 103, 113-137.	3.7	29
113	Monocularly and binocularly evoked visual responses to patterned half-field stimulation. Journal of the Neurological Sciences, 1980, 46, 281-290.	0.3	20
114	Spatial frequency selectivity of periodic complex cells in the visual cortex of the cat. Vision Research, 1978, 18, 665-682.	0.7	43
115	Periodic complex cells in cortical area 19 of the cat. Vision Research, 1978, 18, 347-350.	0.7	5
116	Clinical Manifestations of Brawny Scleritis. American Journal of Ophthalmology, 1978, 85, 781-787.	1.7	30
117	Amaurosis fugax due to isolated atherosclerotic carotid artery disease in a young woman. Annals of Neurology, 1977, 2, 541-542.	2.8	3
118	Topography of the retinal projection upon the superior colliculus of the cat. Vision Research, 1970, 10, 135-143.	0.7	317